Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

W hat a twist! An activist investment fund, Starboard Value, has recently been pushing Pfizer (NYSE: PFE) to increase ...

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock has ...